Q32 Bio (QTTB) Corporate presentation summary

Strategic focus and pipeline development

• Advancing immune therapeutics with a primary focus on alopecia areata (AA), leveraging bempikibart, a dual IL-7/TSLP inhibitor, as a potential new standard of care for severe and very severe AA.

• Pipeline includes ADX-914-XL in preclinical development and a tissue-targeted complement inhibitor platform, with strategic options under evaluation.

• Management team has extensive biotech and immunology expertise, supporting ongoing and future clinical programs.

Clinical trial progress and efficacy data

• SIGNAL-AA Phase 2a Part B showed a 35.3% mean reduction in SALT score at 36 weeks in severe/very severe AA, with 40% achieving SALT-20 response.

• Durable responses observed, including off-drug maintenance and deepening of effect, supporting potential for long-term disease control.

• Bempikibart demonstrated a favorable safety profile with no severe adverse events and minimal injection site reactions.

• Biomarker analysis showed significant decreases in CD3+ T cells, TARC, IgE, and eosinophils, supporting the mechanism of action.

Market opportunity and unmet need

• AA affects approximately 700,000–800,000 patients in the US, with a projected market size exceeding $5B by 2037.

• Significant unmet need remains due to limited advanced therapies and safety concerns with JAK inhibitors.

• Physicians and patients seek safer, more durable, and patient-friendly treatment options.